Design Therapeutics, Inc. (DSGN) Stock Forecast & Analysis
Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Design Therapeutics, Inc. (DSGN:NASDAQ), powered by AI.
- Current Price
- $10.72
- P/E Ratio
- -8.8
- Market Cap
- 615M
- Sector
- Healthcare
What is the Design Therapeutics, Inc. stock price forecast?
Design Therapeutics, Inc. is currently trading at $10.72. View real-time AI analysis on Alpha Lenz.
What is Design Therapeutics, Inc. insider trading activity?
View the latest insider trading data for Design Therapeutics, Inc. on Alpha Lenz.
What is Design Therapeutics, Inc.'s P/E ratio?
Design Therapeutics, Inc.'s P/E ratio is -8.8.
Design Therapeutics, Inc.
NASDAQ · DSGN“Design Therapeutics, Inc. trades at a P/E of -8.8 (undervalued) with modest ROE of -30.7%.”
Ask for details →Company Overview
Design Therapeutics Inc. is a biotechnology company focused on developing treatments for serious degenerative disorders. At the heart of its operations is the use of a proprietary technology platform aimed at addressing the underlying genetic causes of such conditions. Design Therapeutics specializes in creating what they call GeneTAC™ molecules, which are designed to target and modulate the transcription of dysfunctional genes within the human genome. This innovative approach is primarily tailored towards combatting inherited diseases linked to gene expression dysregulation. The company's efforts predominantly impact the health sector, specifically targeting rare genetic and neurological diseases. Founded to bridge the gap between cutting-edge genetic research and clinical application, Design Therapeutics strives to bring new therapeutic options to patients with limited treatment choices. By integrating advancements in gene expression modulation, the company plays a vital role in advancing biotechnology solutions and broadening the scope of personalized medicine.
Company Statistics
FY 2025Profile
Margins
Valuation
Growth (CAGR)
Returns
Financial Health
“Design Therapeutics, Inc. trades at a P/E of -8.8 (undervalued) with modest ROE of -30.7%.”
Ask for details →Frequently Asked Questions
Design Therapeutics, Inc. (ticker: DSGN) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 57 employees. Market cap is $615M.
The current price is $10.72 with a P/E ratio of -8.81x and P/B of 2.89x.
ROE is -30.70%.